Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing With Orbimed For Up To $250 Million
Round Type
Grant
SeattleBiotechnologyHealth CareTherapeuticsDescription
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it has entered into a non-dilutive royalty financing agreement with OrbiMed for up to $250 million. Proceeds from the agreement will strengthen Adaptive’s balance sheet, which stood at over $450 million in cash and marketable securities at the end of the second quarter of 2022, and provide the Company with additional capital to support its growth trajectory and path to profitability.
Quick answer
Adaptive Biotechnologies Corporation raised an undisclosed amount in a Grant round, dated September 12, 2022. Adaptive Biotechnologies Corporation is based in Seattle, Washington, United States.
- How much did Adaptive Biotechnologies Corporation raise?
- Adaptive Biotechnologies Corporation raised an undisclosed amount in a Grant round on September 12, 2022.
- What does Adaptive Biotechnologies Corporation do?
- Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the adaptive immune system's biology to transform disease diagnosis and treatment.
- Where is Adaptive Biotechnologies Corporation based and how big is it?
- Adaptive Biotechnologies Corporation is based in Seattle, Washington, United States. Fundz records about 670 employees.
- Who are the decision-makers at Adaptive Biotechnologies Corporation?
- Fundz holds 1 contact at Adaptive Biotechnologies Corporation, including the Chief People Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Adaptive Biotechnologies Corporation that raised within 45 days of this round, from Fundz verified event records.
- Biofrontera raised $3.7M (Seed) on October 25, 2022.
- MapLight Therapeutics raised $12M on October 25, 2022.
- Insmed Incorporated raised an undisclosed amount (Funding Round) on October 19, 2022.
- Orionis Biosciences raised $55M (Funding Round) on October 19, 2022.
- SURGE Therapeutics raised $26M (Series A) on October 17, 2022.
- Mablink Bioscience raised $30M (Series A) on October 14, 2022.
Who to call at Adaptive Biotechnologies Corporation, and when
A new round usually means Adaptive Biotechnologies Corporation is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Adaptive Biotechnologies Corporation raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Adaptive Biotechnologies Corporation, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Adaptive Biotechnologies Corporation. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Adaptive Biotechnologies Corporation raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Adaptive Biotechnologies Corporation raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.